BC Week In Review | Jun 29, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In...
BC Extra | Jun 28, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
BC Week In Review | Nov 17, 2017
Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
BC Extra | Nov 16, 2017
Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
BC Extra | Apr 26, 2017
Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...
Items per page:
1 - 5 of 5